Pfizer (PFE) Expected to Announce Quarterly Earnings on Tuesday

Pfizer (NYSE:PFE) is expected to be issuing its Q4 2025 results before the market opens on Tuesday, February 3rd. Analysts expect Pfizer to post earnings of $0.56 per share and revenue of $16.9329 billion for the quarter. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 3, 2026 at 10:00 AM ET.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The business had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. On average, analysts expect Pfizer to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Pfizer Trading Up 0.9%

NYSE:PFE opened at $25.87 on Tuesday. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer has a 1-year low of $20.92 and a 1-year high of $27.69. The firm has a market capitalization of $147.09 billion, a price-to-earnings ratio of 15.04 and a beta of 0.47. The business’s 50-day moving average price is $25.41 and its two-hundred day moving average price is $25.00.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Quest Investment Management LLC boosted its holdings in Pfizer by 1.3% during the third quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock worth $809,000 after purchasing an additional 405 shares during the last quarter. WealthCollab LLC lifted its position in Pfizer by 12.5% during the 2nd quarter. WealthCollab LLC now owns 3,985 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 442 shares in the last quarter. Abel Hall LLC boosted its stake in shares of Pfizer by 1.7% during the 3rd quarter. Abel Hall LLC now owns 26,342 shares of the biopharmaceutical company’s stock worth $671,000 after buying an additional 442 shares during the last quarter. Vivaldi Capital Management LP grew its holdings in shares of Pfizer by 3.4% in the 2nd quarter. Vivaldi Capital Management LP now owns 14,438 shares of the biopharmaceutical company’s stock valued at $350,000 after acquiring an additional 472 shares in the last quarter. Finally, Guardian Investment Management increased its position in shares of Pfizer by 4.1% in the third quarter. Guardian Investment Management now owns 14,310 shares of the biopharmaceutical company’s stock valued at $365,000 after acquiring an additional 558 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have commented on PFE. HSBC reaffirmed a “buy” rating and issued a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. UBS Group assumed coverage on Pfizer in a report on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price target for the company. Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $27.88.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.